2 Phase 3 RCTs in 3162 MTX-IR #RA patients Rx w/ either tofacitinib or Otilimab (anti-GMCSF) or placebo, showed otilima
Tweet Content
2 Phase 3 RCTs in 3162 MTX-IR #RA patients Rx w/ either tofacitinib or Otilimab (anti-GMCSF) or placebo, showed otilimab was superior to PBO (ACR20, CDAI LDA HAQ-DI) but was inferior to tofacitinib. Tofa was superior to PBO and otilimab. https://t.co/jrUDs1nfN5 https://t.co/MVsgk0zwLa
Show on Archive Page
On
Display in Search Results
On
PDQ
Off